Supercharge Your Innovation With Domain-Expert AI Agents!

Method of controlling the content of selected component(s) from polymer(s) using molecular sieve(s)

A component content, molecular sieve technology, applied in the field of controlling the content of selected components in one or more polymers, capable of resolving and/or displacing or sequestering inefficient, and/or poor components, Poor component selectivity and other issues

Inactive Publication Date: 2012-02-01
NOVOZYMES BIOPHARMA DK AS
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] Depending on the method chosen and the active agent used, inherent disadvantages of the above techniques are that: repeated applications are often required to achieve the desired balance of components (e.g. repeated precipitation and resuspension or extensive dia-filtration); and / or poor selectivity of components; and / or poor capacity of components; and / or low efficiency of displacement or sequestration; and / or process introduces other components that are difficult to remove later and / or are toxic; and / or process stream conditions need to be manipulated to achieve the desired balance of components

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0102] Example 1 Purification of hyaluronic acid without calcium removal stage

[0103] In this example, a 5 g / l hyaluronic acid solution obtained by fermentation of recombinant Bacillus subtilis was diluted with ordinary tap water, and filtered to remove host cells. The filtrate was then dialyzed extensively against deionized water to remove most of the free calcium not on the HA molecule itself. The resulting dialysis product contained 4.4% by weight of calcium relative to the mass of hyaluronic acid.

Embodiment 2

[0104] Example 2 Purification of hyaluronic acid with conventional calcium removal stage by diafiltration against sodium salts

[0105] Hyaluronic acid was obtained as described in Example 1 in this example. Introducing a calcium control step (not involving the molecular sieves of the present invention) involving competitive displacement of calcium in the presence of excess sodium ions, as follows:

[0106] The hyaluronic acid solution was diafiltered against excess sodium ions. The released calcium ions are thereby removed from the solution by passing through the diafiltration membrane. Calcium ions released from hyaluronic acid may have been equally removed by polymer precipitation. In the present case, the hyaluronic acid solution was diafiltered at constant volume against 3x volumes of 10 wt% sodium sulfate solution, followed by extensive dialysis against deionized water to remove excess sulfate and sodium ions. The resulting product contained 1.2% by weight of calciu...

Embodiment 3

[0107] Example 3 Control of Calcium Content of Hyaluronic Acid Using Cation Exchange Resin

[0108] Hyaluronic acid was produced as described in Example 1 above. The sodium ion form with SO 3 - (>2eq / l) strong cation exchange resins are used to manipulate the calcium ion content of the polymer.

[0109] The performance of the exchange resin is characterized by a series of conditions that are likely to be encountered throughout the hyaluronic acid manufacturing and purification process described above.

[0110] In one example, 1.0 wt% exchange resin was added to a 0.5 wt% hyaluronic acid solution containing 2 wt% calcium relative to hyaluronic acid. After incubation with agitation for 120 minutes, the resin was filtered from solution. The obtained filtrate containing hyaluronic acid had a calcium content of 0.5 wt% calcium relative to hyaluronic acid. After 240 minutes of incubation under the same conditions, the calcium content relative to hyaluronic acid was below dete...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention provides in a first aspect a method for controlling the content of selected component(s) in one or more polymer(s) by: (a) contacting the polymer(s) with at least one molecular sieve; and optionally (b) isolating the polymer from the molecular sieve(s).

Description

field of invention [0001] The present invention relates to methods for controlling the level of selected components in one or more polymers. Background of the invention [0002] Polymers and their derivatives are used in a wide variety of applications. Of particular interest are biopolymers that can be used in the food, cosmetic, pharmaceutical industries. To meet these various applications, it is often necessary to purify the polymer to remove excess components and to further control the balance of components in the final product. [0003] The most abundant heteropolysaccharide in the human body is glycosaminoglycan. Glycosaminoglycans are unbranched sugar polymers consisting of repeating disaccharide units (only keratan sulphate is branched in the core region of the sugar). The disaccharide unit typically comprises one of two modified sugars, N-acetylgalactosamine (GalNAc) or N-acetylglucosamine (GlcNAc), as the first sugar unit. The other unit is usually an uronic aci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C08B37/00C08B37/10
CPCC08B37/0003C08B37/0072
Inventor 埃里克·思韦茨马丁·巴福德波尔·巴赫
Owner NOVOZYMES BIOPHARMA DK AS
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com